Cervical cancer screening and vaccination: understanding the latest guidelines

Tessa Si Chi Lim¹, MBBS, Ida Ismail-Pratt², MBChB, MRCOG, Lay Hoon Goh³, MMed, FCFP

Mrs Lee, a 56-year-old homemaker, visited your clinic requesting for a Pap smear. Her last Pap smear had been done during a postpartum visit at the age of 35 years. Her friend had recently encouraged her to resume cervical cancer screening. Mrs Lee said that she had reached menopause two years ago and did not have any postcoital or postmenopausal bleeding.

WHAT IS CERVICAL CANCER SCREENING?
Cervical cancer screening involves tests to detect abnormal cervical cells at the pre-invasive stage (i.e. cervical pre-cancer). Early treatment can then be instituted to prevent the development of cervical cancer. Two types of cervical smears are used: high-risk human papillomavirus (HR HPV) DNA testing and the Papanicolaou (Pap) smear. The sampling procedure is the same for both; a brush is inserted into the vagina to collect exfoliated cervical cells from the surface of the cervix for testing.¹ HR HPV DNA testing looks for the presence of any of the 14 cancer-causing HPVs, while a Pap smear is a cytology-based test that looks for abnormal cervical cellular changes resulting from persistent HR HPV infection.

Cervical cancer is caused by persistent high-risk HPV infection. Out of the more than 150 types of HPVs that are currently known, 14 are linked to cervical cancer, with Type 16 and 18 causing the majority (70%) of cervical cancers worldwide.² HPV infection is common among young, sexually active women. A local study in 2014 showed that the highest prevalence of HPV infection was in those aged 20–24 years (26.1%).³ However, most HPV infections are transient and will be cleared by the body without increasing the risk of cervical cancer. Studies have shown that 90% of those infected with HPV will be cleared of infection within two years from acquisition, via the host immune system. Risk factors for future cervical cancer development include increased exposure to high-risk HPV (e.g. multiple sexual partners, sexual activity at an early age) or an inability to eradicate the infection owing to an immunocompromised state.⁴

HOW RELEVANT IS THIS TO MY PRACTICE?
Singapore saw an initial decline in the incidence of cervical cancer since the introduction of the national cervical cancer screening programme in 2004. This programme was initially launched as a cytology-only-based programme, with the recommendation that all women aged 25–69 years who had ever had sexual intercourse get a Pap smear done every three years. Data has shown that a screening coverage of at least 70% is required for a screening programme to be effective.⁴ However, data from 2004 to 2008 showed that only 10% of Singaporean women had their routine re-screening.⁵ Over the years, despite efforts made to improve screening uptake, the latest Singapore population health survey showed that the rates still remain at a dismal 48.2%.⁶ In 2013, while 64.8% of Singaporean women reported that they had done at least one Pap smear or HPV DNA test, provides protection from cervical cancer for only a limited time interval.⁷ As cervical cancer develops over a long time-period of 10–20 years,⁸ regular screening is the only effective way to pick up the disease early for treatment.

Currently, screening is available islandwide as part of the Screen for Life programme, in both polyclinics and general practitioner (GP) clinics under the Community Health Assist Scheme (CHAS). Screen for Life is a national screening programme that encourages Singaporean citizens and permanent residents to be screened for chronic conditions such as diabetes mellitus and certain cancers such as colorectal and cervical cancer. The CHAS scheme provides subsidised medical and dental care for Singaporean citizens at GP and dental clinics. Based on the level of subsidy, costs per cervical screening test can range from being free to SGD 5 at CHAS GP Clinics, and up to about SGD 22 at polyclinics for Singaporeans. The Singapore Cancer Society also provides free cervical cancer screening for Singaporeans aged 25 years and above at one of their centres.⁹,¹⁰ Thus, screening is now highly affordable and accessible to all.

WHAT CAN I DO IN MY PRACTICE?
Cervical cancer is preventable, and prevention is achieved not just through screening but also through vaccination. As mentioned, the uptake of cervical cancer screening in Singapore has continuously been suboptimal despite various initiatives introduced by the government. One of the main barriers to screening is lack of understanding of the importance of regular

¹Department of Family Medicine, National University Health System, ²The Obstetrics and Gynaecology Centre, Singapore Medical Group, ³National University Polyclinics, ⁴Division of Family Medicine, NUS Yong Loo Lin School of Medicine, Singapore
Correspondence: Dr Tessa Si Chi Lim, Resident, Department of Family Medicine, NUHS Tower Block, 1E Kent Ridge Rd, Singapore 119228. tessa_lim@nuhs.edu.sg

https://doi.org/10.11622/smedj.2022045
cervical cancer screening. A local study cited the top reasons why Singaporean women had never gone for cervical screening: 39.4% felt that they were healthy and it was unnecessary, while 13.6% had never heard of a Pap smear test. Much remains to be done to correct these misconceptions and raise awareness about screening. Additionally, the uptake of HPV vaccination is low; a study done in a Singaporean tertiary institution in 2016 showed that only 9.8% of the female students had received the HPV vaccine.

Family physicians play a pivotal role in increasing the uptake of these programmes, as they are at the heart of the community and have considerable power to influence the community’s health. Preventive health is an essential part of a family physician’s job scope. In order to be effective advocates for prevention of cervical cancer, all family physicians should continuously enhance their knowledge about important aspects of cervical cancer screening and prevention, such as the role of HPV in screening and HPV vaccines. Various societies in Singapore offer continued medical education in this aspect, including the Singapore Cancer Society, Society for Colposcopy and Cervical Pathology of Singapore, and the Health Promotion Board.

**HPV vaccines as primary prevention against cervical cancer**

HPV vaccines are prophylactic viral-like particles designed to enhance host immunity against certain high-risk HPVs while lacking the ability to infect the host. The safety profile of HPV vaccines is well documented. Currently, there are three types of HPV vaccines (bivalent, quadrivalent and nanovalent) in Singapore. All these vaccines are equally effective in protecting against the most common high-risk HPV types (Type 16 and 18). The main difference among them is the additional coverage provided (Table I).

As exposure to HPV can occur during sexual intercourse, it is recommended that the vaccine be given to adolescents prior to their first sexual contact. Family physicians should target these population groups when advocating for vaccination. In Singapore, HPV vaccination is licensed to be given to both men and women between the age of nine and 26 years for both the bivalent and the quadrivalent vaccines. In September 2020, the nanovalent vaccine was approved to be given to men and women up to the age of 45 years, following emerging evidence of continued protective benefits for these groups.

In May 2019, the Ministry of Health (MOH) launched the national school HPV vaccination programme, which offers the bivalent HPV vaccine to all female Secondary 1 students. The national school HPV vaccination programme, which offers the bivalent HPV vaccine to all female Secondary 1 students.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Cervarix</th>
<th>Gardasil</th>
<th>Gardasil 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protection from HPV-related cancers</td>
<td>• HPV 16 and 18</td>
<td>• HPV 16 and 18</td>
<td>• HPV 16 and 18</td>
</tr>
<tr>
<td></td>
<td>• 70% protection from future cervical cancer</td>
<td>• 70% protection from future cervical cancer</td>
<td>• Additional coverage against five HPV subtypes that cause cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 90% protection from future cervical cancer</td>
</tr>
<tr>
<td>Protection against genital warts</td>
<td>No</td>
<td>Yes (HPV 6 and 11)</td>
<td>Yes (HPV 6 and 11)</td>
</tr>
<tr>
<td></td>
<td>• Polyclinics</td>
<td>• Everywhere else in Singapore, GPs, DSC</td>
<td>• Everywhere else in Singapore, GPs, DSC</td>
</tr>
<tr>
<td></td>
<td>• School HPV vaccination programme</td>
<td>• Covered by Medisave (for females aged 9–26 years)</td>
<td>• Not covered by Medisave</td>
</tr>
<tr>
<td></td>
<td>• Covered by Medisave (for females aged 9–26 years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Licensed in Singapore</td>
<td>Female only (9–26 years of age)</td>
<td>Female and male (9–26 years of age)</td>
<td>Female and male (9–45 years of age)</td>
</tr>
<tr>
<td>Cost for a 3-dose regime</td>
<td>About SGD 400/year</td>
<td>About SGD 400/year</td>
<td>About SGD 600/year</td>
</tr>
</tbody>
</table>

DSC: Department of Sexually Transmitted Infections Control; GP: general practitioner; HPV: human papillomavirus; SCS: Singapore Cancer Society

**Table II. Old vs. new cervical cancer screening guidelines in Singapore.**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All women aged 25–69 years who have ever had sexual intercourse: Pap smear every three years</td>
<td>Women aged 25–29 years old who have ever had sexual intercourse: HPV primary screening every five years</td>
</tr>
<tr>
<td>Discharged from screening</td>
<td>At age 69, if they have two consecutive negative HPV tests in the last ten years, with the latest test done within the last five years</td>
<td></td>
</tr>
</tbody>
</table>

HPV: human papillomavirus
compared to cytology in detecting pre-invasive cervical disease. Other benefits include the increased screening interval, providing better cost-effectiveness compared to conventional cytology screening (16).

The guideline recommends conventional cytology screening for women aged 25–29 years rather than HPV screening. This is because a positive HPV test in this age group is not a true reflection of a woman’s risk of cervical cancer in the future. In this age group, and particularly in Singapore, where uptake of HPV vaccination is low, there is a high incidence of transient HPV infection. (18) Most women would eventually be clear of the HPV infection, without increased risk of cervical cancer in the future. Additionally, there are concerns that high rates of HPV positivity in this age group would result in an increased number of unnecessary colposcopies and invasive interventions such as cervical biopsy and colposcopy treatment. These, in turn, expose women to unnecessary physical and psychological morbidities later. Unnecessary colposcopy treatment has been shown to lead to significant future reproductive and pregnancy-related morbidities as well. (17)

Lastly, if patients have symptoms such as abnormal per vaginal bleeding or suspicious cervical lesions on speculum examination, a cervical smear is inappropriate. Such patients should be referred for further evaluation by a gynaecologist. The aim of cervical cancer screening is to detect women at high risk of pre-invasive cervical disease, and it should be done on asymptomatic women with a normal-looking cervix during speculum examination. Pre-cancer cells and HPV infection do not present with any symptoms and are invisible to the naked eye; screening is the only way to detect their presence.

### INTERPRETATION OF RESULTS

This section serves to complement the local cervical cancer screening guidelines through interpreting the various possible results and explaining the rationale for subsequent steps. The following are some updates on cytology-only screening.

1. Patients who show NILM (negative for intraepithelial lesion and malignancy) and absent endocervical cells no longer need to have an annual Pap smear but should return to routine screening. This is because the absence of endocervical cells is not associated with increased risk of pre-invasive cervical disease. (18)

2. Those who show ASC-US (atypical squamous cells of undetermined significance) no longer need a repeat Pap smear in six months. If cytology shows ASC-US, the laboratory will automatically perform an HPV DNA test on the original sample. If HPV negative, the woman returns to routine screening. If HPV positive, the patient should be referred for colposcopy.

3. If NILM is present and endometrial cells are seen, the guideline varies based on age. The age cut-off for referral to a gynaecologist has now been raised from 40 years to 45 years. As many women aged 40–45 years still have menstrual cycles, benign endometrial cells on Pap smear in this age group do not correlate with significant pathology. (19) However, if the woman is aged below 45 years and has any positive risk factors (abnormal vaginal bleeding, chronic anovulation, family history of endometrial cancer), should also be referred to a gynaecologist for risk assessment of endometrial cancer.

Screening for special populations is not within the scope of this article. These include immunosuppressed women, post-hysterectomy patients and patients with previous abnormal results. More details can be found in the 2019 cervical screening guidelines. (11)

### WHEN SHOULD I REFER TO A SPECIALIST?

Tables III and IV summarise how to manage the various results encountered on cytology and HR HPV testing.

<table>
<thead>
<tr>
<th>Cytology results</th>
<th>Recommended management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unsatisfactory cytology</td>
<td>Treat any infection or atrophy, and repeat cytology in three months</td>
</tr>
<tr>
<td></td>
<td>• Persistently unsatisfactory: perform HPV test</td>
</tr>
<tr>
<td></td>
<td>• NILM: routine screening in three years</td>
</tr>
<tr>
<td>Satisfactory cytology and NILM</td>
<td>Routine screening in three years</td>
</tr>
<tr>
<td>Satisfactory cytology and NILM with absent endocervical cells</td>
<td>Routine screening in three years</td>
</tr>
<tr>
<td>Satisfactory cytology and NILM with specific micro-organism identified</td>
<td>Treat vaginal infection if necessary. (20) Routine screening in three years</td>
</tr>
<tr>
<td>Satisfactory cytology and NILM with inflammatory changes</td>
<td>Treat any infection or atrophy, and repeat cytology in six months.</td>
</tr>
<tr>
<td></td>
<td>• If still showing inflammatory changes, repeat cytology in six months.</td>
</tr>
<tr>
<td></td>
<td>• If the third cytology still shows inflammatory changes, refer to gynaecologist</td>
</tr>
<tr>
<td>Satisfactory cytology and NILM with endometrial cells (&lt; 45 years of age and no risk factors)</td>
<td>Routine screening in three years</td>
</tr>
<tr>
<td>Satisfactory cytology and NILM with endometrial cells (&lt; 45 years of age with risk factors for endometrial cancer)</td>
<td>Refer to gynaecologist</td>
</tr>
<tr>
<td>Satisfactory cytology and NILM with endometrial cells (≥ 45 years of age, regardless of risk factors)</td>
<td>Refer to gynaecologist</td>
</tr>
<tr>
<td>ASC-US + HPV negative</td>
<td>Routine screening in three years</td>
</tr>
<tr>
<td>ASC-US + HPV positive</td>
<td>Refer for colposcopy</td>
</tr>
<tr>
<td>All other abnormal cytology result from ASC-H (atypical squamous cells, cannot exclude high-grade lesion) and above</td>
<td>Refer for colposcopy</td>
</tr>
</tbody>
</table>

ASC-US: atypical squamous cells of undetermined significance; HPV: human papillomavirus; NILM: negative for intraepithelial lesion and malignancy.

16 Practice Integration & Lifelong Learning

17

18

19

20

11

127
**Table IV. A guide to management of HR HPV DNA test results.**

<table>
<thead>
<tr>
<th>HR HPV DNA test result</th>
<th>Recommended management</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV not detected</td>
<td>Routine screening in five years</td>
</tr>
<tr>
<td>HPV 16 positive</td>
<td>Refer for colposcopy</td>
</tr>
<tr>
<td>HPV 18 positive</td>
<td>Refer for colposcopy</td>
</tr>
<tr>
<td>HPV non-16/18 positive + abnormal cytology (ASC-US and above)</td>
<td>Refer for colposcopy</td>
</tr>
</tbody>
</table>
| HPV non-16/18 positive + NILM cytology | Repeat HPV DNA test in one year  
  - All persistent HPV cases that are non-16/18 positive for the second time: refer to colposcopy  
  - Negative repeat HPV DNA test: resume routine screening in five years |

ASC-US: atypical squamous cells of undetermined significance; HR HPV: high-risk human papillomavirus; NILM: negative for intraepithelial lesion and malignancy

**TAKE HOME MESSAGES**

1. Cervical cancer is highly preventable through both screening and vaccination.
2. Screening uptake is the most important factor for a successful cervical cancer screening programme. Uptake in Singapore is still suboptimal, and primary care physicians have a vital role to play in promoting understanding and uptake of screening in the local community.
3. It is important for primary care physicians to be familiar with the appropriate tests and relevant intervals for cervical cancer screening, especially with the introduction of HR HPV testing in the latest guidelines.
4. Primary care physicians should know how to interpret screening results and the subsequent steps, including indications for a gynaecology referral.
5. Preventive health goes hand in hand with screening. Primary care physicians should be familiar with the various HPV vaccinations available and advocate vaccination for those in the relevant age groups.

As Mrs Lee was in the 30–69-year age group, you performed a high-risk human papillomavirus (HPV) test for her, which was negative. You also reminded her to take another HPV test in five years’ time. She felt reassured and thanked you for your time. She wanted to bring her 24-year-old daughter to see you to discuss HPV vaccination.

**REFERENCES**

SINGAPORE MEDICAL COUNCIL CATEGORY 3B CME PROGRAMME
(Code SMJ 202203A)

1. Cervical cancer is caused by persistent human papillomavirus (HPV) infection.  
2. It is inappropriate to do cervical cancer screening for a woman with abnormal per vaginal bleeding. She should be referred to a gynaecologist for further investigations.  
3. Pap smears are more cost-effective than high-risk (HR) HPV testing.  
4. A first cervical cytology that you did for a 27-year-old woman shows inflammatory changes. You should treat any underlying infections before repeating the smear in six months.  
5. An HR HPV test, if normal, should be repeated every three years.  
6. HR HPV tests showing HPV 16 or 18 positive should also be considered for colposcopy.  
7. The incidence of invasive cervical cancer and related mortality is reduced by increased uptake of cervical cancer screening and HPV vaccinations.  
8. All women aged 25 to 69 years, whether virgo intacta or not, should be screened for cervical cancer.  
9. More than 90% of HPV infections spontaneously clear after two years.  
10. The most common HPV-causing cancers are HPV 6 and 11.  
11. A 30-year-old woman who is unvaccinated against HPV is eligible to receive the HPV vaccine.  
12. All women can be discharged from cervical cancer screening at the age of 69 years as long as the last single HPV test is negative.  
13. The presence of endometrial cells on a Pap smear is worrying in certain groups of women.  
14. If ASC-US (atypical squamous cells of undetermined significance) is present on cervical cytology, an HR HPV test should be done for further evaluation.  
15. HPV-vaccinated women follow a different cervical cancer screening schedule from non-HPV-vaccinated women.  
16. A 56-year-old woman’s HR HPV test shows non-16/18 positive. She should be urgently referred to a gynaecologist.  
17. For cytology results, any result showing ASC-H (atypical squamous cells, cannot exclude high-grade lesion) or worse should be referred for colposcopy, whether urgently or not.  
18. Special populations such as immunocompromised patients follow a different cervical cancer screening schedule from the general population.  
19. The screening interval for Pap smears for those aged 25–29 years should be every three years.  
20. Women aged 30–69 years should be screened with HR HPV screening.

Doctor’s particulars:
Name in full: ____________________________ MCR no.: ____________________________
Specialty: ____________________________ Email: ____________________________

SUBMISSION INSTRUCTIONS:
Visit the SMJ website: http://www.smj.org.sg/current-issue and select the appropriate quiz. You will be redirected to the SMA login page.
For SMA member: (1) Log in with your username and password (if you do not know your password, please click on ‘Forgot your password?’). (2) Select your answers for each quiz and click ‘Submit’.  
For non-SMA member: (1) Create an SMJ CME account or log in with your SMJ CME username and password (for returning users). (2) Make payment of SGD 21.40 (inclusive of 7% GST) via PayPal to access this month’s quizzes. (3) Select your answers for each quiz and click ‘Submit’.  
RESULTS:
(1) Answers will be published online in the SMJ May 2022 issue. (2) The MCR numbers of successful candidates will be posted online at the SMJ website by 31 May 2022. (3) Passing mark is 60%. No mark will be deducted for incorrect answers. (4) The SMJ editorial office will submit the list of successful candidates to the Singapore Medical Council. (5) One CME point is awarded for successful candidates. (6) SMC credits CME points according to the month of publication of the CME article i.e. points awarded for a quiz published in the December 2021 issue will be credited for the month of December 2021, even if the deadline is in February 2022.